title: Vesnarinone represses the fibrotic changes in murine lung injury induced by bleomycin.
abstract: We investigated the potential usefulness of vesnarinone, a novel cytokine inhibitor, for the treatment of lung fibrosis using a murine model of bleomycin (BLM)-induced pulmonary fibrosis. Mice were fed a control diet (n=42), or a diet containing low (n=42) or high (n=42) dose of vesnarinone. Dietary intake of vesnarinone minimized the BLM toxicity as reflected by significant decreases in numbers of inflammatory cells, KC, and soluble TNF receptors in the bronchoalveolar lavage fluid. A quantitative evaluation of histology demonstrated significantly mild lung parenchymal lesions in BLM-treated mice fed with diet containing high dose of vesnarinone than in the control diet group. Consistent with the histopathology, hydroxyproline levels in lung tissue from BLM-treated mice fed with diet containing vesnarinone were significantly lower than that from mice fed with control diet. We concluded that vesnarinone inhibits BLM-induced pulmonary fibrosis, at least in part, by the inhibition of acute lung injuries in the early phase.
authors.affiliation: First Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, Japan.
authors.forename: Minoru
authors.initials: M
authors.lastname: Inage
authors.forename: Hidenori
authors.initials: H
authors.lastname: Nakamura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Saito
authors.forename: Shuichi
authors.initials: S
authors.lastname: Abe
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Hino
authors.forename: Noriaki
authors.initials: N
authors.lastname: Takabatake
authors.forename: Kyoko
authors.initials: K
authors.lastname: Terashita
authors.forename: Manabu
authors.initials: M
authors.lastname: Ogura
authors.forename: Shuichi
authors.initials: S
authors.lastname: Kato
authors.forename: Tetsumi
authors.initials: T
authors.lastname: Hosokawa
authors.forename: Makoto
authors.initials: M
authors.lastname: Sata
authors.forename: Hitonobu
authors.initials: H
authors.lastname: Tomoike
mesh_terms: D000818:Animals; D001761:Bleomycin; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D016207:Cytokines / Q000037:antagonists & inhibitors*; D004032:Diet; D006820:Hyaluronic Acid / Q000097:blood; D006909:Hydroxyproline / Q000378:metabolism; D008168:Lung / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D011658:Pulmonary Fibrosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011719:Pyrazines; D011804:Quinolines / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D018124:Receptors, Tumor Necrosis Factor / Q000032:analysis; D012720:Severity of Illness Index
chemical_list: D016207:Cytokines; D011719:Pyrazines; D011804:Quinolines; D018124:Receptors, Tumor Necrosis Factor; D001761:Bleomycin; C041667:vesnarinone; D006820:Hyaluronic Acid; D006909:Hydroxyproline